Abstract
Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Current Neuropharmacology
Title: Release of Adenosine and ATP During Ischemia and Epilepsy
Volume: 7 Issue: 3
Author(s): Nicholas Dale and Bruno G. Frenguelli
Affiliation:
Abstract: Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Export Options
About this article
Cite this article as:
Dale Nicholas and Frenguelli G. Bruno, Release of Adenosine and ATP During Ischemia and Epilepsy, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152146
DOI https://dx.doi.org/10.2174/157015909789152146 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Commentary: Participation of Sox-1 Expression and Signaling of β-Catenin in the Pathophysiology of Generalized Seizures in Cerebellum of Rat
CNS & Neurological Disorders - Drug Targets Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Anti-Inflammatory Immunotherapy for Multiple Sclerosis/Experimental Autoimmune Encephalomyelitis (EAE) Disease
Current Medicinal Chemistry The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Spontaneous Recurrent Seizures Mediated Cardiac Dysfunction via mTOR Pathway Upregulation: A Putative Target for SUDEP Management
CNS & Neurological Disorders - Drug Targets Congenital Cytomegalovirus Prevention, Awareness and Policy Recommendations - A Scoping Study
Infectious Disorders - Drug Targets A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals Design and In Vitro Evaluation of a Novel Vaginal Drug Delivery System Based on Gelucire
Current Drug Delivery Epigenetic Regulation of Trinucleotide Repeat Expansions and Contractions and the “Biased Embryos” Hypothesis for Rapid Morphological Evolution
Current Genomics Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued)